This Phase IV randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of Tribulus terrestris (TT; Tribestan®) in 180 men aged 18–65 with mild to moderate erectile dysfunction (ED), with or without hypoactive sexual desire disorder (HSDD). Participants received 1,500 mg/day of TT (3×2 tablets) or placebo for 12 weeks.
